Most Popular in OBR vs. Most Popular in the Media

OBR readers are oncology stakeholders – oncologists and oncology focused health care professionals, pharmaceutical developers and manufacturers, investment bank analysts, consultants, and even patients too. In consideration of the OBR audience, what were the most read articles in OBR daily over the span of the annual ASCO meeting, and how does that compare to what the media thought were the big stories?

Here is a list of the most read stories on OBR daily since Saturday:

Costly Newer Drugs No Better in Breast Cancer Study
(Reuters) June 4, 2012 – A pair of newer drugs proved no better, and by some measures inferior, to the older and cheaper chemotherapy agent paclitaxel in patients with locally advanced or metastatic breast cancer, according to results of a late stage study.
read article

A Drug for Advanced Melanoma Is Found to Prolong Patients’ Lives
(New York Times) June 4, 2012 – A new type of drug prolonged the lives of patients with advanced melanoma in a clinical trial, potentially adding to a growing number of therapies for a disease that was once nearly untreatable.
read article

Roche Smart-Bomb Cancer Drug Delays Breast-Tumor Growth
(Bloomberg Businessweek) June 3, 2012 – An experimental breast cancer drug from Roche Holding AG that carries chemotherapy directly into malignant cells while bypassing healthy ones delayed tumors longer and with fewer side effects than an established therapy.
read article

J&J Scores Big With Prostate Cancer Pill
(TheStreet) June 2, 2012 – Johnson & Johnson’s Zytiga improved survival in “pre-chemo” prostate cancer patients by 33% and more than doubled the time before cancer worsened compared to control, according to results from a phase III study to be presented today at the American Society of Clinical Oncology (ASCO) annual meeting.
read article

US FDA Rejects Merck/Ariad Sarcoma Drug
(Reuters) June 5, 2012 – U.S. drugs regulators rejected an experimental sarcoma medicine from Merck and Ariad Pharmaceuticals on Tuesday, asking for more clinical trials, Merck said.
read article

In contrast, here are the stories that our editors think made the biggest splash in the media outlets:

Bristol Immune Drug Shows Promise in Three Cancers
(Reuters) June 2, 2012 – An experimental Bristol-Myers Squibb drug helped shrink tumors in patients with advanced melanoma, kidney and lung cancers in a preliminary trial, raising hopes for yet another drug that can wake up the immune system and train it to attack cancer cells.
read article

Roche Smart-Bomb Cancer Drug Delays Breast-Tumor Growth
(Bloomberg Businessweek) June 3, 2012 – An experimental breast cancer drug from Roche Holding AG that carries chemotherapy directly into malignant cells while bypassing healthy ones delayed tumors longer and with fewer side effects than an established therapy.
read article

A Drug for Advanced Melanoma Is Found to Prolong Patients’ Lives
(New York Times) June 4, 2012 – A new type of drug prolonged the lives of patients with advanced melanoma in a clinical trial, potentially adding to a growing number of therapies for a disease that was once nearly untreatable.
read article

Ariad’s Ponatinib Shown to Aid Leukemia Patients in Study
(Bloomberg Businessweek) June 4, 2012 – Ariad Pharmaceuticals Inc. said its experimental leukemia drug ponatinib helped patients with a mutation resistant to other therapies in a study the company will use to seek approval from U.S. and European regulators.
read article

Bayer Drug Stalls Stomach Tumors After Standard Treatment
(Bloomberg Businessweek) June 4, 2012 – Bayer AG’s experimental cancer drug regorafenib delayed progression of stomach cancer in patients who weren’t benefiting from standard treatments, potentially giving doctors a third weapon to battle gastrointestinal tumors.
read article

Why the difference? Probably because OBR readership is full of people toiling in the industry everyday. Maybe the media outlets view things differently than others, or have other motives? Either way you look at it, it was a strong annual meeting this year for exciting news, data, and studies.

by Don Sharpe

article register

Recent Posts

Recent Comments

Archives

Categories

Post a Comment

You must be logged in to post a comment